Modicus Prime, founded in 2020, is at the forefront of innovation in the intersection of AI, Biopharma, and Computer Vision. Headquartered in the United States, the company strives to transform how pharmaceutical manufacturers integrate AI, ensuring that systems are auditable and compliant by design, living up to its slogan of "Infrastructure enabling pharmaceutical manufacturers to deploy AI systems that are auditable and compliant by design."
Their flagship product, the Modicus Platform, is engineered to make AI implementations audit-ready for both pharmaceutical companies and Contract Development and Manufacturing Organizations (CDMOs). This appeal has caught the eye of strategic investors.
In a recent funding round, Modicus Prime raised $3.50M through a seed investment led by Silverton Partners and Alumni Ventures, with the investment closing on 01 July 2024. This capital infusion is expected to accelerate their platform's adoption and support further product development.